RAPT Therapeutics Inc. (NASDAQ: RAPT) stock jumped 1.51% on Friday to $19.50 against a previous-day closing price of $19.21. With 0.81 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.55 whereas the lowest price it dropped to was $18.87. The 52-week range on RAPT shows that it touched its highest point at $31.45 and its lowest point at $15.59 during that stretch. It currently has a 1-year price target of $41.67. Beta for the stock currently stands at 0.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RAPT was up-trending over the past week, with a rise of 2.79%, but this was up by 0.49% over a month. Three-month performance dropped to -9.76% while six-month performance rose 1.09%. The stock lost -27.64% in the past year, while it has lost -1.52% so far this year. A look at the trailing 12-month EPS for RAPT yields -2.70 with Next year EPS estimates of -3.22. For the next quarter, that number is -0.75. This implies an EPS growth rate of -2.00% for this year and -8.40% for next year.
Float and Shares Shorts:
At present, 38.33 million RAPT shares are outstanding with a float of 31.41 million shares on hand for trading. On Aug 30, 2023, short shares totaled 4.05 million, which was 11.79% higher than short shares on Jul 30, 2023. In addition to Dr. Brian Russell Wong M.D., Ph.D. as the firm’s CEO, Pres & Director, Mr. Rodney K. B. Young serves as its CFO, Principal Accounting Officer & Sec.
Through their ownership of 100.38% of RAPT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 45.54% of RAPT, in contrast to 40.69% held by mutual funds. Shares owned by individuals account for 26.75%. As the largest shareholder in RAPT with 10.15% of the stake, Fidelity Management & Research Co holds 3,485,663 shares worth 3,485,663. A second-largest stockholder of RAPT, T. Rowe Price Associates, Inc., holds 3,427,371 shares, controlling over 9.98% of the firm’s shares. Perceptive Advisors LLC is the third largest shareholder in RAPT, holding 2,288,493 shares or 6.66% stake. With a 5.89% stake in RAPT, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,021,825 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 3.50% of RAPT stock, is the second-largest Mutual Fund holder. It holds 1,200,884 shares valued at 22.94 million. SPDR S&P Biotech ETF holds 3.20% of the stake in RAPT, owning 1,098,498 shares worth 20.98 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, RAPT reported revenue of $886.00k and operating income of -$18.91M. The EBITDA in the recently reported quarter was -$18.64M and diluted EPS was -$0.62.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RAPT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RAPT analysts setting a high price target of $48.00 and a low target of $31.00, the average target price over the next 12 months is $39.91. Based on these targets, RAPT could surge 146.15% to reach the target high and rise by 58.97% to reach the target low. Reaching the average price target will result in a growth of 104.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded RAPT stock several times over the past three months with 2 Buys and 1 Sells. In these transactions, 1,380 shares were bought while 2,500 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 10 over the past year. The total number of shares bought during that period was 10,529 while 40,242 shares were sold.